NASDAQ:CFRX ContraFect (CFRX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.05▼$0.0650-Day Range$0.05▼$0.0752-Week Range$0.04▼$13.02Volume910,200 shsAverage Volume1.39 million shsMarket Capitalization$535,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ContraFect alerts: Email Address Ad Crypto 101 MediaBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.Click here to get The Crypto Bull Run Millionaire Blueprint now. About ContraFect Stock (NASDAQ:CFRX)ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York.Read More Ad Crypto 101 MediaBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.Click here to get The Crypto Bull Run Millionaire Blueprint now. CFRX Stock News HeadlinesApril 16, 2024 | finance.yahoo.comRegenETP, Inc. (RGTPQ)January 9, 2024 | morningstar.comContraFect Corp CFRXQJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.November 19, 2023 | morningstar.comContraFect Corp CFRXNovember 14, 2023 | washingtonpost.comContraFect: Q3 Earnings SnapshotOctober 23, 2023 | benzinga.comWhy Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving PremarketOctober 16, 2023 | msn.comWhy Is ContraFect (CFRX) Stock Up 23% Today?October 16, 2023 | finance.yahoo.comContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.October 10, 2023 | benzinga.comWhy Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving PremarketSeptember 21, 2023 | finance.yahoo.comCFRX: IND Application for CF-370 Submitted to FDA…September 19, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: ContraFect (CFRX), Boston Scientific (BSX)September 19, 2023 | finance.yahoo.comContraFect to Present at the ASM/ESCMID Joint Conference on Drug DevelopmentSeptember 18, 2023 | finance.yahoo.comContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370August 28, 2023 | finance.yahoo.comContraFect to Present at the World Anti-Microbial Resistance Congress 2023August 17, 2023 | finance.yahoo.comCFRX: CF-370 IND to be Filed in 3Q23…August 15, 2023 | markets.businessinsider.comContraFect (CFRX) Receives a Buy from Maxim GroupAugust 14, 2023 | sfgate.comContraFect: Q2 Earnings SnapshotSee More Headlines Receive CFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CFRX CUSIPN/A CIK1478069 Webwww.contrafect.com Phone(914) 207-2300FaxN/AEmployees23Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($19.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,150,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-138.70% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($19.92) per share Price / Book0.00Miscellaneous Outstanding Shares10,700,000Free Float10,639,000Market Cap$535,000.00 OptionableNot Optionable Beta0.29 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Roger James Pomerantz FACP (Age 66)M.D., Chairman, CEO & President Comp: $970.72kMr. Michael Messinger CPA (Age 48)Chief Financial Officer Comp: $543.14kMs. Natalie Bogdanos J.D. (Age 54)General Counsel, Corporate Secretary & Data Protection Officer Comp: $531.2kMr. Matthew Salamone P.H.R.SPHR, Vice President of Human ResourcesDr. Gary Woodnutt (Age 66)Senior Vice President of Translational Sciences & Preclinical Development Dr. William Garrett Nichols M.D. (Age 54)M.S., Interim Chief Medical Officer More ExecutivesKey CompetitorsOncoSec MedicalNASDAQ:ONCSTransCode TherapeuticsNASDAQ:RNAZPhio PharmaceuticalsNASDAQ:PHIOPaxMedicaNASDAQ:PXMDAltamira TherapeuticsNASDAQ:CYTOView All Competitors CFRX Stock Analysis - Frequently Asked Questions How were ContraFect's earnings last quarter? ContraFect Co. (NASDAQ:CFRX) released its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($10.40) earnings per share for the quarter, beating the consensus estimate of ($22.64) by $12.24. When did ContraFect's stock split? ContraFect's stock reverse split on Tuesday, February 14th 2023. The 1-80 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of ContraFect own? Based on aggregate information from My MarketBeat watchlists, some other companies that ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Verastem (VSTM), Vaxart (VXRT), Matinas BioPharma (MTNB), VBI Vaccines (VBIV) and Novavax (NVAX). This page (NASDAQ:CFRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraFect Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ContraFect With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.